Shanghai Pharmaceuticals (601607.SH) subsidiary's treprostinil diethanolamine inhalation powder aerosol receives clinical trial approval

Zhitong Finance APP news, Shanghai Pharmaceuticals (601607.SH) announced that recently, its subsidiary Shanghai Shangyao Ruier Pharmaceutical Co., Ltd. received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration for treprostinil diethanolamine inhalation powder.